IL-13Ralpha2-targeted ligands (Memorial Sloan-Kettering Cancer Center/Wake Forest School of Medicine)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameIL-13Ralpha2-targeted ligands (Memorial Sloan-Kettering Cancer Center/Wake Forest School of Medicine)
Drug Alias NameIL-13 targeted quadruple mutant (Memorial Sloan-Kettering Cancer Center/Wake Forest School of Medicine)interleukin-13 receptor alpha 2-targeted ligands (Memorial Sloan-Kettering Cancer Center/Wake Forest School of Medicine)131I-TQM-13TQM-13125I-TQM-13 +[6] 
ClassificationRadiation-emitting products > Radioactive diagnostic agentBiologics > Protein drugs > Recombinant proteinDiagnostic agent (In vivo) +[4] 
Mechanisms of ActionInterleukin-13 receptor subunit alpha-2 modulatorsPositron-emission tomography enhancers
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWake Forest University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWake Forest UniversityMemorial Sloan Kettering Cancer Center
Active IndicationsN/A
Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A